- Home
- XTNT vs OTLK Comparison
XTNT vs OTLK Comparison
Compare XTNT & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTNT
- OTLK
- Stock Information
- Founded
- XTNT N/A
- OTLK 2010
- Country
- XTNT United States
- OTLK United States
- Employees
- XTNT N/A
- OTLK N/A
- Industry
- XTNT Biotechnology: Biological Products (No Diagnostic Substances)
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XTNT Health Care
- OTLK Health Care
- Exchange
- XTNT Nasdaq
- OTLK Nasdaq
- Market Cap
- XTNT 60.9M
- OTLK 56.3M
- IPO Year
- XTNT N/A
- OTLK 2016
- Fundamental
- Price
- XTNT $0.47
- OTLK $1.25
- Analyst Decision
- XTNT Strong Buy
- OTLK Strong Buy
- Analyst Count
- XTNT 1
- OTLK 5
- Target Price
- XTNT $3.00
- OTLK $10.20
- AVG Volume (30 Days)
- XTNT 33.4K
- OTLK 376.0K
- Earning Date
- XTNT 03-06-2025
- OTLK 05-14-2025
- Dividend Yield
- XTNT N/A
- OTLK N/A
- EPS Growth
- XTNT N/A
- OTLK N/A
- EPS
- XTNT N/A
- OTLK N/A
- Revenue
- XTNT $117,267,000.00
- OTLK N/A
- Revenue This Year
- XTNT $15.56
- OTLK N/A
- Revenue Next Year
- XTNT $22.39
- OTLK $288.46
- P/E Ratio
- XTNT N/A
- OTLK N/A
- Revenue Growth
- XTNT 28.44
- OTLK N/A
- 52 Week Low
- XTNT $0.33
- OTLK $0.87
- 52 Week High
- XTNT $1.14
- OTLK $10.21
- Technical
- Relative Strength Index (RSI)
- XTNT 45.30
- OTLK 36.31
- Support Level
- XTNT $0.45
- OTLK $1.15
- Resistance Level
- XTNT $0.54
- OTLK $1.42
- Average True Range (ATR)
- XTNT 0.04
- OTLK 0.12
- MACD
- XTNT 0.00
- OTLK -0.01
- Stochastic Oscillator
- XTNT 36.55
- OTLK 24.71
About XTNT Xtant Medical Holdings Inc.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.